ABUS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Arbutus Biopharma Corp (ABUS) is not a strong buy for a beginner, long-term investor at this time. While there are positive catalysts such as the Fast Track designation for its drug imdusiran and promising clinical trial results, the company's weak financial performance, reduced price target by analysts, and lack of significant trading signals suggest that it is better to hold off on investing until more favorable conditions emerge.
The technical indicators show a bullish trend with MACD positively expanding, bullish moving averages (SMA_5 > SMA_20 > SMA_200), and the price trading above key pivot levels. However, RSI at 71.329 indicates the stock is nearing overbought territory, suggesting caution.
The FDA Fast Track designation for imdusiran and its promising clinical trial results, which show potential to significantly improve the lives of chronic hepatitis B patients, are strong positive catalysts.
Weak financial performance in Q4 2025 with significant declines in revenue (-33.23% YoY), net income (-70.03% YoY), and EPS (-71.43% YoY). Additionally, analysts have reduced the price target due to concerns over the Moderna patent appeal, increasing uncertainty.
The company's financial performance in Q4 2025 was weak, with revenue, net income, and EPS all showing significant declines year-over-year. Gross margin remained stable at 100%, but this does not offset the overall negative trend.
Analysts maintain a Buy rating but have reduced the price target from $7 to $5.50 due to increased probability (75%) of Moderna winning the '1498 appeal, which could impact a $1.3 billion payment to Arbutus.
